Processa Pharmaceuticals, Inc. Common closed at $1.94 on Nov 4, down 0.26%, 79.1% below its 52-week closing high. Volume of 22.0K shares was 0.11× its 20-day average (below normal).
Split-adjusted performance: +27.3% over one month, -29.6% over six months, -79.1% over one year.
Short interest was 46.5K shares at the Oct 15 settlement, up 1022.9% from the prior report (2.2% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| PCSAProcessa Pharmaceuticals | $1.94 | −0.26% | −29.6% | — | — | — | $5.4M | |
| PULMPulmatrix | $1.52 | +14.29% | +11.8% | — | — | — | $5.6M | Compare |
| SCNXScienture Holdings | $3.42 | −0.87% | −65.0% | — | −821.3% | — | $5.6M | Compare |
| ACXPAcurx Pharmaceuticals | $1.03 | +0.98% | −50.7% | — | — | — | $5.6M | Compare |
| LGVNLongeveron | $1.78 | 0.00% | −79.6% | −9.2% | −2116.0% | — | $5.7M | Compare |
| IMNNImunon | $0.9070 | +0.78% | −66.5% | — | — | — | $5.1M | Compare |
| SKYESkye Bioscience | $1.14 | −6.56% | −83.3% | — | — | — | $5.0M | Compare |
| AZTRAzitra | $0.8157 | −7.71% | −66.7% | — | — | — | $4.9M | Compare |
| XBIOXenetic Biosciences | $2.01 | −3.37% | −36.6% | +12.0% | −140.7% | — | $4.7M | Compare |
No recent articles focused on Processa Pharmaceuticals.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
